PCI Pharma Services Executive and Leadership Team

Tom DeWeerdt, the Chief Financial Officer at PCI Pharma Services, manages the fiscal health and long-term capital strategy of the organization. Overseeing global financial planning and analysis, the Chief Financial Officer ensures that investment in analytical services and formulation development remains aligned with corporate growth objectives. This leadership role involves managing complex budgetary requirements across multiple international locations to support the expansion of clinical trial supply capabilities. By monitoring market trends and financial performance, Tom DeWeerdt directly impacts the strategic direction of the company. DeWeerdt coordinates with other C-suite leaders to evaluate potential acquisitions and infrastructure investments that enhance the competitive position of the firm. Through rigorous financial oversight and risk management, the Chief Financial Officer secures the capital resources required to maintain the company's status as a premier provider of integrated pharmaceutical services in the global healthcare sector.

Brad Payne, the Chief Operating Officer at PCI Pharma Services, directs all internal manufacturing and packaging operations across the global network. Overseeing the efficiency of commercial production lines, the Chief Operating Officer ensures that complex pharmaceutical supply chains remain agile and compliant with international standards. This leadership role involves optimizing resource allocation to support high-volume distribution requirements throughout the United States and Europe. By streamlining cross-functional workflows, Brad Payne directly impacts the company's ability to meet rigorous client timelines for drug delivery. Payne maintains constant alignment with the Board to ensure operational capacity matches the evolving demands of the global healthcare market. Through the implementation of advanced manufacturing technologies, the Chief Operating Officer drives significant improvements in throughput and quality control, ultimately securing the operational foundation necessary for sustained growth and reliable service delivery to pharmaceutical partners worldwide.

Laila Rubi, the Chief Operating Officer, Clinical Quality Documents at PCI Pharma Services, governs the integrity and regulatory compliance of all clinical documentation processes. Overseeing the rigorous standards required for clinical trial supply, the Chief Operating Officer, Clinical Quality Documents ensures that every phase of development meets stringent global health authority requirements. This leadership role involves architecting robust quality management systems that support the safe and efficient distribution of pharmaceutical products. By standardizing documentation protocols, Laila Rubi directly impacts the reliability of the clinical trial services provided to global healthcare clients. Rubi collaborates with regulatory bodies and internal teams to mitigate compliance risks during the critical stages of drug development. Through the meticulous oversight of quality assurance frameworks, the Chief Operating Officer, Clinical Quality Documents maintains the high level of trust necessary for the company to operate effectively within the complex, highly regulated pharmaceutical manufacturing landscape.

Halley Liu, the President at PCI Pharma Services, defines the overarching corporate strategy and market positioning for the entire organization. Overseeing the integration of analytical services, formulation development, and supply chain management, the President ensures that the company maintains a cohesive approach to serving the global healthcare industry. This leadership role involves driving long-term growth initiatives and fostering partnerships that expand the company's footprint across the United States and Europe. By aligning departmental goals with the broader mission of delivering high-quality pharmaceutical solutions, Halley Liu directly impacts the company's competitive advantage. Liu works closely with the Board to execute high-level business objectives and ensure the firm remains at the forefront of pharmaceutical innovation. Through decisive leadership and a focus on operational excellence, the President guides the organization toward achieving its vision of becoming the preferred partner for complex pharmaceutical manufacturing and distribution needs.

Brian Keesee, the President, Clinical Trial Services at PCI Pharma Services, leads the specialized division dedicated to the end-to-end management of clinical trial supplies. Overseeing the complex logistics of storage, distribution, and QP services, the President, Clinical Trial Services ensures that global clinical programs receive timely and accurate support. This leadership role involves coordinating with pharmaceutical companies to navigate the unique challenges of international clinical trials, including temperature-controlled storage and rapid distribution. By optimizing the clinical supply chain, Brian Keesee directly impacts the speed and success of drug development programs for clients. Keesee manages the strategic expansion of clinical service capabilities to meet the growing demand for integrated trial support in diverse geographic markets. Through the application of specialized expertise and operational focus, the President, Clinical Trial Services maintains the high standards of precision required to support the advancement of new therapies from development to clinical application.

Michelle Logan, the President, Development & Manufacturing at PCI Pharma Services, directs the technical and production teams responsible for formulation development and commercial manufacturing. Overseeing the transition of products from early-stage development to full-scale commercial packaging, the President, Development & Manufacturing ensures that technical processes remain scalable and efficient. This leadership role involves managing the integration of advanced analytical services into the manufacturing workflow to guarantee product quality and consistency. By driving innovation in formulation and production techniques, Michelle Logan directly impacts the company's ability to support clients through the entire product lifecycle. Logan collaborates with cross-functional teams to ensure that manufacturing facilities in the United States and Europe operate at peak performance. Through the strategic management of development and manufacturing assets, the President, Development & Manufacturing secures the company's capacity to deliver high-quality pharmaceutical products that meet the evolving needs of the global healthcare market.